| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA1 Protein | 20 | 2023 | 216 | 1.890 |
Why?
|
| BRCA2 Protein | 17 | 2025 | 175 | 1.830 |
Why?
|
| Genetic Predisposition to Disease | 37 | 2025 | 2474 | 1.820 |
Why?
|
| Precision Medicine | 9 | 2021 | 454 | 1.450 |
Why?
|
| Breast Neoplasms | 26 | 2023 | 3157 | 1.440 |
Why?
|
| Ovarian Neoplasms | 15 | 2023 | 801 | 1.380 |
Why?
|
| Pharmacogenetics | 7 | 2024 | 456 | 1.260 |
Why?
|
| Genetic Testing | 9 | 2024 | 565 | 1.140 |
Why?
|
| Mutation | 24 | 2023 | 4374 | 0.950 |
Why?
|
| Genes, BRCA2 | 7 | 2019 | 162 | 0.920 |
Why?
|
| Genes, BRCA1 | 7 | 2019 | 192 | 0.910 |
Why?
|
| Heterozygote | 17 | 2025 | 382 | 0.800 |
Why?
|
| Primary Health Care | 3 | 2021 | 391 | 0.780 |
Why?
|
| Germ-Line Mutation | 9 | 2025 | 382 | 0.780 |
Why?
|
| Genetics, Population | 2 | 2021 | 437 | 0.670 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 66 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2022 | 2494 | 0.650 |
Why?
|
| Genome-Wide Association Study | 12 | 2021 | 1765 | 0.640 |
Why?
|
| Patients | 1 | 2021 | 108 | 0.630 |
Why?
|
| Health Literacy | 1 | 2021 | 77 | 0.620 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 1798 | 0.620 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 209 | 0.550 |
Why?
|
| Humans | 73 | 2025 | 96105 | 0.450 |
Why?
|
| Multifactorial Inheritance | 3 | 2025 | 202 | 0.450 |
Why?
|
| Genomics | 5 | 2021 | 857 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2016 | 80 | 0.430 |
Why?
|
| Risk Factors | 22 | 2025 | 5961 | 0.420 |
Why?
|
| Female | 50 | 2025 | 50028 | 0.400 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 484 | 0.390 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 469 | 0.370 |
Why?
|
| Pharmacogenomic Testing | 3 | 2018 | 107 | 0.370 |
Why?
|
| Adult | 31 | 2025 | 28721 | 0.360 |
Why?
|
| Risk Assessment | 10 | 2025 | 2480 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 296 | 0.350 |
Why?
|
| Middle Aged | 28 | 2025 | 28368 | 0.350 |
Why?
|
| Neoplasms | 6 | 2025 | 3248 | 0.350 |
Why?
|
| Physicians | 2 | 2021 | 707 | 0.340 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 40 | 0.320 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 72 | 0.310 |
Why?
|
| Alleles | 6 | 2021 | 1157 | 0.310 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 50 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 595 | 0.290 |
Why?
|
| Body Height | 2 | 2019 | 108 | 0.290 |
Why?
|
| Mastectomy | 3 | 2016 | 270 | 0.290 |
Why?
|
| Biological Specimen Banks | 3 | 2024 | 72 | 0.290 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 238 | 0.280 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 393 | 0.280 |
Why?
|
| Pedigree | 7 | 2020 | 982 | 0.270 |
Why?
|
| Aged | 20 | 2025 | 20968 | 0.260 |
Why?
|
| Male | 27 | 2025 | 45863 | 0.250 |
Why?
|
| Quantitative Trait Loci | 6 | 2021 | 632 | 0.250 |
Why?
|
| Chromosome Mapping | 3 | 2020 | 1083 | 0.250 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 286 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1230 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2019 | 815 | 0.230 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2025 | 12 | 0.230 |
Why?
|
| Colorectal Neoplasms | 3 | 2025 | 1069 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 540 | 0.230 |
Why?
|
| Penetrance | 1 | 2025 | 48 | 0.230 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 417 | 0.220 |
Why?
|
| Prostate | 2 | 2022 | 423 | 0.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2025 | 50 | 0.220 |
Why?
|
| Patient Transfer | 1 | 2014 | 108 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1670 | 0.200 |
Why?
|
| Community Health Planning | 3 | 2018 | 22 | 0.200 |
Why?
|
| Software | 2 | 2020 | 698 | 0.190 |
Why?
|
| Phenotype | 7 | 2023 | 2578 | 0.190 |
Why?
|
| DNA Copy Number Variations | 3 | 2022 | 191 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1957 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 7229 | 0.190 |
Why?
|
| Exome | 3 | 2021 | 141 | 0.180 |
Why?
|
| Medical History Taking | 2 | 2025 | 88 | 0.180 |
Why?
|
| Inpatients | 1 | 2014 | 347 | 0.170 |
Why?
|
| Genotype | 7 | 2021 | 1881 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2019 | 1423 | 0.170 |
Why?
|
| Health Personnel | 2 | 2021 | 241 | 0.170 |
Why?
|
| Young Adult | 7 | 2021 | 7025 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2014 | 312 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2020 | 302 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 171 | 0.170 |
Why?
|
| Intensive Care Units | 1 | 2014 | 460 | 0.170 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 20 | 0.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 57 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2014 | 372 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2024 | 413 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 326 | 0.160 |
Why?
|
| Urinary Tract | 1 | 2020 | 33 | 0.160 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2463 | 0.160 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 121 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2023 | 4671 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 180 | 0.150 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Nipples | 2 | 2016 | 38 | 0.150 |
Why?
|
| Hexokinase | 1 | 2019 | 22 | 0.150 |
Why?
|
| Illinois | 1 | 2021 | 531 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2024 | 3110 | 0.150 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 52 | 0.150 |
Why?
|
| Databases, Genetic | 3 | 2018 | 284 | 0.140 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 555 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2019 | 254 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 76 | 0.140 |
Why?
|
| United Kingdom | 3 | 2025 | 192 | 0.140 |
Why?
|
| Prognosis | 6 | 2019 | 4028 | 0.130 |
Why?
|
| Exons | 2 | 2016 | 454 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 606 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 2860 | 0.130 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 301 | 0.130 |
Why?
|
| Genes, Modifier | 1 | 2017 | 5 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2020 | 447 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 1267 | 0.130 |
Why?
|
| Community Pharmacy Services | 1 | 2016 | 6 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2024 | 10287 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 301 | 0.130 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 563 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 64 | 0.120 |
Why?
|
| Professional Role | 1 | 2016 | 42 | 0.120 |
Why?
|
| Point Mutation | 2 | 2016 | 247 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 61 | 0.120 |
Why?
|
| Genetic Carrier Screening | 1 | 2016 | 59 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 65 | 0.120 |
Why?
|
| Adenomatous Polyps | 1 | 2016 | 15 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 78 | 0.120 |
Why?
|
| Transcriptome | 2 | 2020 | 769 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 569 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 42 | 0.120 |
Why?
|
| Codon, Terminator | 1 | 2015 | 22 | 0.120 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 31 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 45 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2017 | 260 | 0.120 |
Why?
|
| Genes, Dominant | 1 | 2015 | 116 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1876 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 128 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 901 | 0.110 |
Why?
|
| Connective Tissue Diseases | 1 | 2015 | 75 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 155 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2021 | 481 | 0.110 |
Why?
|
| Ovariectomy | 1 | 2014 | 91 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 99 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2016 | 307 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2014 | 46 | 0.100 |
Why?
|
| Estrone | 1 | 2013 | 10 | 0.100 |
Why?
|
| G2 Phase | 1 | 2013 | 33 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 412 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 453 | 0.100 |
Why?
|
| Adolescent | 6 | 2020 | 9895 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2019 | 1546 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 310 | 0.100 |
Why?
|
| Infant | 3 | 2020 | 3363 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 514 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2016 | 683 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 143 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2020 | 1730 | 0.090 |
Why?
|
| Cell Division | 1 | 2013 | 705 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 1089 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 346 | 0.090 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 547 | 0.090 |
Why?
|
| Micrognathism | 1 | 2010 | 11 | 0.080 |
Why?
|
| Eye Abnormalities | 1 | 2010 | 41 | 0.080 |
Why?
|
| Karyotyping | 1 | 2010 | 257 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2010 | 229 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2022 | 404 | 0.070 |
Why?
|
| Gene Duplication | 1 | 2010 | 129 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1215 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 366 | 0.070 |
Why?
|
| Chicago | 1 | 2013 | 1506 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 208 | 0.070 |
Why?
|
| Gene Expression | 3 | 2016 | 1320 | 0.070 |
Why?
|
| Family | 2 | 2020 | 332 | 0.070 |
Why?
|
| Genome, Human | 1 | 2012 | 824 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2019 | 218 | 0.060 |
Why?
|
| Peer Review | 1 | 2006 | 24 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 74 | 0.060 |
Why?
|
| Documentation | 1 | 2006 | 103 | 0.060 |
Why?
|
| Homozygote | 2 | 2023 | 208 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 231 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 668 | 0.060 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.060 |
Why?
|
| Radiation Oncology | 1 | 2006 | 124 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 245 | 0.050 |
Why?
|
| Protein Binding | 2 | 2020 | 1560 | 0.050 |
Why?
|
| United States | 4 | 2024 | 7768 | 0.050 |
Why?
|
| Hospital Rapid Response Team | 1 | 2014 | 28 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2024 | 245 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 713 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2014 | 137 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2090 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 111 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 32 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 996 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1535 | 0.050 |
Why?
|
| Virulence | 1 | 2023 | 279 | 0.050 |
Why?
|
| Computational Biology | 2 | 2016 | 586 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 136 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 183 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2022 | 82 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 910 | 0.040 |
Why?
|
| Biopsy | 2 | 2015 | 1220 | 0.040 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 23 | 0.040 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 2000 | 1 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2014 | 594 | 0.040 |
Why?
|
| Amphibian Proteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 108 | 0.040 |
Why?
|
| Morpholinos | 1 | 2020 | 13 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1963 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1346 | 0.040 |
Why?
|
| Xenopus | 1 | 2020 | 130 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 96 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1619 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 212 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 135 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2020 | 159 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 70 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 2086 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 234 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 2537 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 336 | 0.040 |
Why?
|
| Estrogens | 1 | 2020 | 203 | 0.040 |
Why?
|
| Retinitis Pigmentosa | 1 | 2019 | 37 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 69 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 167 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 90 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 271 | 0.040 |
Why?
|
| Mice | 3 | 2020 | 12537 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 703 | 0.040 |
Why?
|
| Child | 2 | 2020 | 7625 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 190 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pregnancy-Specific beta 1-Glycoproteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Transcription Factors, TFII | 1 | 2017 | 2 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 5 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 240 | 0.030 |
Why?
|
| Disclosure | 1 | 2018 | 111 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3639 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 84 | 0.030 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2017 | 44 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 107 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 22 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 235 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 443 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 86 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1715 | 0.030 |
Why?
|
| RNA Splice Sites | 1 | 2016 | 58 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 155 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 110 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 70 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 553 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2161 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 404 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 360 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 99 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 653 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 328 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 9175 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2016 | 159 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 393 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2016 | 623 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 220 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2019 | 463 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2880 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 190 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 344 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 650 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 580 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 308 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3974 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 28891 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 120 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 682 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 2344 | 0.020 |
Why?
|
| Skin | 1 | 2015 | 605 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1268 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3040 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 381 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 1157 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 1985 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 777 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 709 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 432 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1562 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 367 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1805 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 1137 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 986 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 558 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1816 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1471 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3927 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2778 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 5580 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2000 | 7 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2000 | 67 | 0.010 |
Why?
|
| Africa | 1 | 2000 | 107 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 109 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 159 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 151 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 829 | 0.010 |
Why?
|